regulatory

Harvested Evidence

processedconfidence: 100.0%

Source

STAT News RSS

Author / Entity

Unknown

Published

2026-09-11

Engine Version

Extracted Signal

engine inference

Lack of approved therapies specifically targeting muscle loss in Spinal Muscular Atrophy (SMA) patients, requiring novel therapeutic approaches beyond existing gene and RNA therapies.

Urgency Score

7.00

Willingness to Pay

0.90

Original Source

immutable record

Collected: 5h agoView Original ↗

STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss By Jonathan WosenSep

Intelligence Relationships

supports / contradicts

Supports

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Opportunity

Lack of effective pharmacological treatments for deafness

Processing History

audit log

Fetched At

9/12/2026, 12:33:07 AM

Engine Version

Ingestion Run

—

Trace ID

66c032c1...

Harvested Evidence

Extracted Signal

Original Source

Intelligence Relationships

Supports

Processing History

Validation Workflow

Contradicts

Activity & Collaboration